durvalumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
durvalumab

GtoPdb Ligand ID: 7985

Synonyms: anti-B7H1 monoclonal antibody | Imfinzi® | MEDI-4736 | MEDI4736

durvalumab is an approved drug (FDA (2017), EMA (2018))

Compound class: Antibody

Comment: Durvalumab is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A patent search suggests that the development and use of durvalumab may be covered by patent WO2011066389 [4], although we cannot verify this by peptide sequence matches as no sequences from this patent are pulled in a protein BLAST with the light or heavy variable regions of durvalumab peptide sequences. An X-ray crystal structure of the PD-L1/durvalumab complex has been submitted to the RCSB PDB (accession 5X8M) [3].

No information available.

No information available.

Summary of Clinical Use
Durvalumab (MEDI-4736) was 'fast tracked' to Phase 3 clinical trial, then receiving full FDA approval in May 2017 for the treatment of advanced/metastatic bladder cancer (urothelial carcinoma) in patients who have already received platinum-containing chemotherapy. Since its first approval, durvalumab has been granted FDA permissions for perioperative use in early-stage resectable NSCLC, muscle-invasive bladder cancer, and early-stage gastric and gastroesophageal junction (GEJ) cancers.

Summary of Clinical Use

Durvalumab (MEDI-4736) was 'fast tracked' to Phase 3 clinical trial, then receiving full FDA approval in May 2017 for the treatment of advanced/metastatic bladder cancer (urothelial carcinoma) in patients who have already received platinum-containing chemotherapy. Since its first approval, durvalumab has been granted FDA permissions for perioperative use in early-stage resectable NSCLC, muscle-invasive bladder cancer, and early-stage gastric and gastroesophageal junction (GEJ) cancers.

Mechanism Of Action and Pharmacodynamic Effects
Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug’s mechanism of action enables the immune cells to detect and destroy tumour cells.

Mechanism Of Action and Pharmacodynamic Effects

Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug’s mechanism of action enables the immune cells to detect and destroy tumour cells.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT04592913	Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer	Phase 3 Interventional	AstraZeneca	The phase 3 Matterhorn trial	1-2

External links
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)

External links

For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)